SK Biopharm buys license for epilepsy drug candidate from U.S. firm

🇰🇷 Yonhap News (KR) —
SK Biopharm buys license for epilepsy drug candidate from U.S. firm

AI Summary

South Korea’s SK Biopharmaceuticals has acquired license rights for an epilepsy drug candidate from a U.S. pharmaceutical firm. This move represents an expansion of SK Biopharm’s drug pipeline and cross-border pharmaceutical collaboration.

SEOUL, Aug. 26 (Yonhap) -- SK Biopharmaceuticals Co., a pharmaceutical affiliat...

Deals Health AI & Tech SK Biopharmaceuticals epilepsy drug license acquisition pharmaceuticals U.S. company drug development

Read original source →